PMID- 17106244
OWN - NLM
STAT- MEDLINE
DCOM- 20070524
LR  - 20221009
IS  - 1538-4047 (Print)
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Linking)
VI  - 5
IP  - 12
DP  - 2006 Dec
TI  - Expression of melanoma-associated antigens in human dendritic cells pulsed with 
      an interleukin-2 gene encoded vaccinia melanoma oncolysate (rIL-2VMO).
PG  - 1654-7
AB  - Dendritic cells (DCs) possess the unique abilities to initiate a primary immune 
      response and to present antigens to naive T lymphocytes. Recently, there has been 
      a rapidly growing interest in the use of DCs in active specific immunotherapy 
      (ASI) for the treatment of patients with cancer. In the present study, we 
      determined the ability of DCs to express Melanoma-Associated Antigens (MAAs) from 
      a polyvalent Melanoma Vaccine (DC-MelVac; Patent #11221/5) developed in our 
      facility. The vaccine consists of a recombinant IL-2 gene-encoded vaccinia 
      melanoma oncolysate (rIL-2VMO) derived from an established human melanoma cell 
      line. Our results show that r-IL2VMO-pulsed DCs express MAAs presented by the 
      Mel-2 melanoma cell line oncolysate used in this study. We believe that these 
      promising results will prove useful as an active specific immunotherapeutic agent 
      for patients with Stage III melanoma.
FAU - Aydin, Nebil
AU  - Aydin N
AD  - Saint Vincent's Catholic Medical Center, New York Medical College, and 
      Metropolitan Hospital Center, New York, New York 10029, USA.
FAU - Jack, Angela
AU  - Jack A
FAU - Montenegro, Grace
AU  - Montenegro G
FAU - Boyes, Christopher
AU  - Boyes C
FAU - Alam, Khorshed
AU  - Alam K
FAU - Wallack, Marc K
AU  - Wallack MK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061207
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interleukin-2)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Antigen-Presenting Cells/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines
MH  - Dendritic Cells/*immunology/ultrastructure
MH  - Humans
MH  - Interleukin-2/*genetics
MH  - Melanoma/*immunology
MH  - Neoplasm Proteins/*immunology
MH  - Recombinant Proteins/immunology
MH  - Reference Values
MH  - T-Lymphocytes/immunology
PMC - PMC9491305
EDAT- 2006/11/16 09:00
MHDA- 2007/05/26 09:00
PMCR- 2022/09/21
CRDT- 2006/11/16 09:00
PHST- 2006/11/16 09:00 [pubmed]
PHST- 2007/05/26 09:00 [medline]
PHST- 2006/11/16 09:00 [entrez]
PHST- 2022/09/21 00:00 [pmc-release]
AID - 3375 [pii]
AID - 10903375 [pii]
AID - 10.4161/cbt.5.12.3375 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2006 Dec;5(12):1654-7. doi: 10.4161/cbt.5.12.3375. Epub 2006 
      Dec 7.